Oesophageal adenocarcinoma and prior diagnosis of Barrett's oesophagus: A population-based study

Gut

Volumn 64, Issue 1, 2015, Pages 20-25

  Bhat, Shivaram K ^a   McManus, Damian T ^b   Coleman, Helen G ^a   Johnston, Brian T ^c   Cardwell, Christopher R ^a   McMenamin, Úna ^a   Bannon, Finian ^d   Hicks, Blanaid ^a   Kennedy, Grace ^a   Gavin, Anna T ^d   Murray, Liam J ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b BELFAST CITY HOSPITAL   (United Kingdom)

^c ROYAL VICTORIA HOSPITAL   (United Kingdom)

^d QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POPULATION RESEARCH; RETROSPECTIVE STUDY; SURVIVAL TIME; UNITED KINGDOM; ADENOCARCINOMA; COMPLICATION; ESOPHAGEAL NEOPLASMS; SURVIVAL;

ADENOCARCINOMA; AGED; BARRETT ESOPHAGUS; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84919706217     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2013-305506     Document Type: Article

References (24)

1. Cook MB, Chow WH, Devesa SS. Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977-2005. Br J Cancer 2009; 101 (5): 855-9.
2. Bosetti C, Levi F, Ferlay J, et al. Trends in oesophageal cancer incidence and mortality in Europe. Int J Cancer 2008; 122: 1118-29.
3. Polednak AP Trends in survival for both histologic types of esophageal cancer in US surveillance, epidemiology and end results areas. Int J Cancer 2003; 105: 98-100.
4. British Society of Gastroenterology. Guidelines for the diagnosis and management of Barrett's columnar-lined oesophagus|Oesophageal|Clinical Guidelines [Online]. 2005. http://www.bsg.org.uk/clinical-guidelines/oesophageal/guidelines-for-the-diagnosis-and-management-of-barrett-s-columnar-lined-oesophagus.html (accessed 7 Jun 2011).
5. Wang KK, Sampliner RE. Updated guidelines for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterology 2008; 103(3): 788-97.
6. Bytzer P, Christensen PB, Damkier P, et al. Adenocarcinoma of the esophagus and Barrett's esophagus: a population-based study. Am J Gastroenterol 1999; 94 (1): 86-91.
7. Cooper GS, Kou TD, Chak A. Receipt of previous diagnoses and endoscopy and outcome from esophageal adenocarcinoma: a Population-Based Study with temporal trends. Am J Gastroenterol 2009; 104(6): 1356-62.
8. Streitz JM Jr, Andrews CW Jr, Ellis FH Jr Endoscopic surveillance of Barrett's esophagus. Does it help? J Thorac Cardiovasc Surg 1993; 105: 383-7;discussion 387-388
9. Van Sandick JW, van Lanschot JJ, Kuiken BW, et al. Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut 1998; 43(2): 216-22.
10. Corley D, Levin T, Habel L, et al. Surveillance and survival in Barrett's adenocarcinomas: A population-based study. Gastroenterology 2002; 122: 633-40.
11. Kramer BS, Croswell JM. Cancer screening: the clash of science and intuition. Annu Rev Med 2009; 60: 125-37.
12. Kirsh VA, Chiarelli AM, Edwards SA, et al. Tumor characteristics associated with mammographic detection of breast cancer in the Ontario breast screening program. J Natl Cancer Inst 2011; 103: 942-50.
13. Auvinen A, Määttänen L, Stenman UH, et al. Lead-time in prostate cancer screening (Finland). Cancer Causes and Control 2002; 13: 279-85.
14. Bhat S, Coleman HG, Yousef F, et al. Risk of Malignant Progression in Barrett's Esophagus Patients: Results from a Large Population-Based Study. J Natl Cancer Inst 2011; 103: 1049-57.
15. American Joint Committee on Cancer, and American Cancer Society. AJCC cancer staging manual. New York: Springer-Verlag, 2002.
16. Edge S, American Joint Committee on Cancer. AJCC cancer staging manual. New York: Springer, 2010.
17. Duffy SW, Nagtegaal ID, Wallis M, et al. Correcting for lead time and length bias in estimating the effect of screen detection on cancer survival. Am J Epidemiol 2008; 168: 98-104.
18. Lawrence G, Wallis M, Allgood P, et al. Population estimates of survival in women with screen-detected and symptomatic breast cancer taking account of lead time and length bias. Breast Cancer Res Treat 2009; 116: 179-85.
19. Jankowski J, Barr H. Improving surveillance for Barrett's oesophagus: AspECT and BOSS trials provide an evidence base. BMJ 2006; 332: 1512.
20. Peters JH, Clark GW, Ireland AP, et al. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg 1994; 108: 813-21;discussion 821-822
21. Inadomi JM Surveillance in Barrett's esophagus: a failed premise. Keio J Med 2009; 58(1): 12-18.
22. Yoon HH, Khan M, Shi Q, et al. The prognostic value of clinical and pathologic factors in esophageal adenocarcinoma: a mayo cohort of 796 patients with extended follow-up after surgical resection. Mayo Clin Proc 2010; 85: 1080-9.
23. Dikken JL, Coit DG, Klimstra DS, et al. Prospective impact of tumor grade assessment in biopsies on tumor stage and prognostic grouping in gastroesophageal adenocarcinoma. Cancer 2012; 118: 349-57.
24. Northern Ireland Statistics and Research Agency. NISRA - Migration statistics. 2009. [Online]. http://www.nisra.gov.uk/demography/default.asp18.htm (accessed 4 Mar 2012).